Course

New Agents, New Targets: How Recently Approved Biologics Are Shifting the Pendulum of Care in Psoriatic Arthritis

We will take a look at current and anticipated guideline recommendations for treatment of PsA, the efficacy and safety of biologic and other agents, considerations in the selection and switching of therapy, and real-life practice trends.

0 out of 4 steps completed0%
0 Lessons

NEW AGENTS, NEW TARGETS: How Recently Approved Biologics Are Shifting the Pendulum of Care in Psoriatic Arthritis

PROVIDED BY

Support for this activity has been made possible through educational grants from Lilly, AbbVie, Celgene, and Janssen

TARGET AUDIENCE

This activity has been designed to meet the educational needs of nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

ACTIVITY DESCRIPTION

In this issue of Rheumatology Nurse Practice, we’ll take a look at current and anticipated guideline recommendations for treatment of PsA, the efficacy and safety of biologic and other agents, considerations in the selection and switching of therapy, and real-life practice trends.

LEARNING OBJECTIVES

After participating in the activity, learners should be better able to:

  • Discuss key components of consensus treatment guidelines for the treatment of psoriatic arthritis (PsA)
  • Review efficacy and safety data for biologic and small molecule therapeutics approved by the U.S. Food and Drug Administration for the treatment of PsA
  • Assess common reasons for discontinuing and switching therapies in patients with PsA
  • Analyze real-world use of biologics and small molecules in your personal practice for the treatment of patients with PsA and consider primary reasons for over- or under-utilization of these agents

DISCLOSURE STATEMENT

According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

RELATIONSHIPS ARE ABBREVIATED AS FOLLOWS:

E: Educational planning committee
G: Grant/research support recipient
A: Advisor/review panel member
C: Consultant
S: Stock shareholder
SB: Speaker bureau
PE: Promotional event talks
H: Honoraria
O: Other

DISCLOSURES AS FOLLOWS:

Linda Grinnell-Merrick, MS, NP-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Celgene, Janssen, Novartis/SB; Lilly, Sanofi/C.

Monica Richey, MSN, ANP-CP/GNP, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Eileen J. Lydon, MA, RN, ANP-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Novartis, AbbVie/SB; Horizon, Sanofi/C.

Amanda Mixon, PA-C, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Lilly/C,SB; Celgene, Novartis/SB; Pfizer, Regeneron/C.

Annette Hendricks disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

PLANNING COMMITTEE

Kim Cheramie, MSN, RN-BC, Lead Nurse Planner, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Alexandra Howson, MA, PhD, CHCP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

INDEPENDENT CLINICAL PEER REVIEWER

This newsletter was reviewed by Tiffany Clark, CNP. Ms. Clark has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

OFF-LABEL PRODUCT DISCLOSURE

There will be no discussion of investigational and/or off-label use of pharmaceutical products or devices within this activity.

ACCREDITATION AND CREDIT DESIGNATION

Nurses

Rheumatology Nurses Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).

Rheumatology Nurses Society designates this educational activity for 3.2 contact hours (3.2 pharmacotherapeutic contact hours).

METHOD OF PARTICIPATION

There are no fees to participate in the activity. Participants must review the activity information, including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please go to rnsnurse.com/rnpce and complete the post-test (achieving a passing grade of 70% or greater) and program evaluation. Your certificate will be emailed to you upon completion.

COPYRIGHT

© 2018. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).